Paris-based biopharmaceutical company Signadori Bio has successfully closed a seed extension financing round, bringing its total capital raised to €11.1 million. The investment saw participation from new investor Taiho Ventures alongside existing backers Sofinnova Partners and Invivo Partners. These proceeds will advance the company's innovative in vivo engineered monocyte immunotherapy platform designed to combat solid tumours.
Advancing a Novel Immunotherapy Platform
Signadori Bio is developing a unique approach that engineers monocytes directly within the body to enhance the immune system's anti-tumour capabilities. This strategy aims to overcome the immunosuppressive tumour microenvironment, a major hurdle for existing cancer treatments. The platform seeks to address key limitations of current immunotherapies, particularly for patients with solid tumours.
The newly secured capital will be instrumental in progressing the company's lead programme, SiB-2101, towards lead candidate nomination. Furthermore, the financing will fuel the continued development of its proprietary in vivo monocyte engineering platform. The company also plans to strategically expand its scientific and operational teams to support its accelerated growth.
Strategic Investor Confidence
The financing round highlights significant investor confidence in Signadori's pioneering work, marked by the addition of Taiho Ventures. This new partnership joins the continued commitment from foundational investors Sofinnova Partners and Invivo Partners. This collective backing provides a strong financial foundation for the company's next stage of preclinical development.
Dr. Selwyn Ho, Chief Executive Officer of Signadori Bio, called the financing an important milestone for the company. He emphasized that the platform has the potential to unlock a new class of more accessible and effective immunotherapies. Dr. Ho also formally welcomed Taiho Ventures, expressing enthusiasm for the collaboration with the company's investors.
Representing the new investor, Seiji Miyahara of Taiho Ventures praised Signadori Bio's highly differentiated strategy in immuno-oncology. He noted the company's compelling preclinical data and strong scientific foundation position it well to address unmet needs. Taiho Ventures is excited to support the team as it enters its next critical development phase.
Matthieu Coutet, Chair of the Board and Partner at Sofinnova Partners, commented on the company's strong progress since its inception. He affirmed that Signadori has made great strides in validating its platform and demonstrating its therapeutic potential. This new funding will enable the company to accelerate its development strategy towards clinical translation.
Pioneering Research and Future Outlook
The company's scientific foundation is built upon groundbreaking research conducted at Gustave Roussy, a world-leading cancer centre. Signadori Bio was co-founded by Dr. Jean-Luc Perfettini and Professor Nathalie Chaput, who pioneered the core technology. This strong academic linkage underscores the innovative nature of the company's therapeutic approach.
Signadori Bio's vision is to create off-the-shelf immunotherapies that can be administered directly to patients. By engineering monocytes in vivo, the company bypasses the complex manufacturing processes associated with traditional cell therapies. This approach promises a more scalable and accessible treatment option for patients with solid tumours.
With its total seed funding now at €11.1 million, Signadori Bio is poised to accelerate its mission to transform solid tumour treatment. The strong backing from a syndicate of specialized life sciences investors validates its novel in vivo immunotherapy platform. As the company advances its lead candidate, it moves closer to delivering a potentially groundbreaking therapy to patients.